Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. on November 15, 2023, reporting events occurring on November 14, 2023. The filing serves to disseminate a press release containing financial information for the quarter ended September 30, 2023. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbols BIAF (Common Stock) and BIAFW (Warrants).
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the financial data for the quarter ended September 30, 2023, is contained within the attached press release (Exhibit 99.1), which is not included in the provided text.
Material Changes
No material changes versus prior periods are detailed in the text of this Form 8-K. The filing acts as a conduit for the press release rather than a standalone financial analysis.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, nor will it be incorporated by reference into other SEC filings. No specific guidance, outlook, or risk factors are enumerated in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 14, 2023) for actual financial figures for the quarter ended September 30, 2023.
- Verify the company's status as an emerging growth company (indicated as yes in the filing).
- Confirm the trading status of Common Stock (BIAF) and Warrants (BIAFW) on The Nasdaq Stock Market LLC.
- Note that the financial data in this filing is not incorporated by reference into future SEC filings.